日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan

在日本,伊沙妥昔单抗联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤的体弱患者

Tagami, Nami; Uchiyama, Michihiro; Suzuki, Kenshi; Shirai, Heigoroh; Seto, Takeshi; Iida, Shinsuke

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

伊沙妥昔单抗联合泊马度胺-地塞米松治疗复发/难治性多发性骨髓瘤:日本上市后监测

Tagami, Nami; Uchiyama, Michihiro; Suzuki, Kenshi; Shirai, Heigoroh; Seto, Takeshi; Nishina, Satoshi; Iida, Shinsuke